tert-Butyl 4-(hydroxymethyl)-3,3-dimethylpiperidine-1-carboxylate

Catalog No.: 
ACAMGJ051
CAS No.: 
2605227-22-1
Molecular Formula: 
C13H25NO3
Molecular Weight: 
243.35
tert-Butyl 4-(hydroxymethyl)-3,3-dimethylpiperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg98%$439.00In stockInquiry
250mg98%$702.00In stockInquiry
500mg98%$1170.00In stockInquiry
1g98%$1755.00In stockInquiry
5g98%$5263.00InquiryInquiry
10g98%$8771.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(hydroxymethyl)-3,3-dimethylpiperidine-1-carboxylate
IUPAC Nametert-butyl 4-(hydroxymethyl)-3,3-dimethylpiperidine-1-carboxylate
MDL No.MFCD35083116
Molecular FormulaC13H25NO3
Molecular Weight243.35
SMILESO=C(N1CC(C)(C)C(CO)CC1)OC(C)(C)C
InChI KeyLUWGOFJUQSIQNK-UHFFFAOYSA-N
Synonym1-Piperidinecarboxylic acid, 4-(hydroxymethyl)-3,3-dimethyl-, 1,1-dimethylethyl ester;tert-Butyl 4-(hydroxymethyl)-3,3-dimethylpiperidine-1-carboxylate;(1-Boc-3,3-dimethyl-4-piperidyl)methanol
CAS No.2605227-22-1

Synthetic Route by SureRoute

1. ACAMGJ051 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHSGM052 route compound structure diagram
    ACHSGM0521915004-57-7In Stock
  2. Then
  3. ACAMGJ051 route product structure diagram
    ACAMGJ0512605227-22-1In Stock
Inquiry

2. ACAMGJ051 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACAMGJ051 route product structure diagram
    ACAMGJ0512605227-22-1In Stock
Inquiry

3. ACAMGJ051 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACAMGJ051 route product structure diagram
    ACAMGJ0512605227-22-1In Stock
Inquiry

Comments (0)